Highlight
- Combining the BCL-2 inhibitor venetoclax with inotuzumab ozogamicin (INO) achieves a 95.5% complete remission rate in relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).
- High rates of measurable residual disease (MRD) negativity were observed using both flow cytometry and next-generation sequencing assays.
- The combination demonstrated an acceptable safety profile with manageable hematologic toxicities and no early mortality.
- MRD negativity correlated with baseline BCL-2 dependence, while resistance mechanisms included MCL-1 dependence and CD22 antigen loss.
